Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 1/20 | 0.58 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.58 |
| ▸ | IDO1 | P14902 | 2/20 | 0.54 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.54 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 2/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20791914 | 0.84 | ADRA1A (0.49) | ADRA1ATAAR1IDO1MTNR1AMTNR1B | |
| SCHEMBL14271357 | 0.83 | IDO1 (0.57) | ADRA1ATAAR1IDO1HTR2AHTR2C | |
| SCHEMBL681333 | 0.81 | ADRA1A (0.64) | ADRA1ATAAR1IDO1MTNR1AMTNR1B | |
| SCHEMBL5267466 | 0.80 | ADRA1A (0.62) | ADRA1ATAAR1IDO1MTNR1AMTNR1B | |
| SCHEMBL13900365 | 0.78 | MTNR1A (0.57) | TAAR1IDO1MTNR1AMTNR1BAOC3 | |
| SCHEMBL15217977 | 0.78 | ADRA1A (0.64) | ADRA1ATAAR1IDO1MTNR1AMTNR1B | |
| SCHEMBL6506680 | 0.76 | ADRA1A (0.57) | ADRA1ATAAR1IDO1MTNR1AMTNR1B | |
| SCHEMBL29814877 | 0.76 | MTNR1A (0.59) | ADRA1ATAAR1MTNR1AMTNR1BHSD17B10 | |
| SCHEMBL5154843 | 0.75 | ADRA1A (0.70) | ADRA1ATAAR1IDO1MTNR1AMTNR1B | |
| SCHEMBL27002039 | 0.75 | MTNR1A (0.66) | ADRA1ATAAR1MTNR1AMTNR1BHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10464925-B2 | Methods to induce targeted protein degradation through bifunctional molecules | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-20180134684-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10464925-B2 | Methods to induce targeted protein degradation through bifunctional molecules | CRBN, MDM2, MYCBP | ADRA1A 4618/4885TAAR1 4375/4885IDO1 3745/4885 |
| US-20180134684-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | CRBN, MDM2, MYCBP | ADRA1A 4618/4885TAAR1 4375/4885IDO1 3745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.